Clinical studies with solvent detergent-treated products

Transfusion Medicine Reviews

Volumn 10, Issue 4, 1996, Pages 303-311

  Pehta, J C ^a  

^a Melville Biologics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DETERGENT; FIBRIN GLUE; IMMUNOGLOBULIN; SOLVENT;

BLOOD TRANSFUSION; CONTAMINATION; HEPATITIS A VIRUS; PARVOVIRUS; PLASMA; REVIEW; SAFETY; VIRUS; VIRUS TRANSMISSION;

EID: 0029809164     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-7963(96)80006-X     Document Type: Article

References (39)

1. Prince A Horowitz B Brotman B Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether Vox Sang 46 1984 36 43
2. Prince A Horowitz B Brotman B Sterilization of hepatitis and HTLV-III viruses by exposure to Tri(n-butyl) phosphate and sodium cholate Lancet i 1986 706 710
3. Edwards CA Piet MPJ Chin S Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives Vox Sang 52 1987 53 59
4. Piet MPJ Chin S Prince A The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation Transfusion 30 1990 591 598
5. Horowitz B Bonomo R Prince A Solvent/detergent treated plasma: A virus-inactivated substitute for fresh frozen plasma Blood 79 1992 826 831
6. Horowitz MS Rooks C Horowitz B Virus safety of solvent/detergent treated antihaemophilic factor concentrate Lancet ii 1988 186 189
7. (abstr) Horowitz MS Valinsky J Absence of antibody to hepatitis C in patients receiving a solvent/detergent treated antihemophilic factor concentrate XIX International Congress of the World Federation of Hemophilia Washington, DC 1990 27
8. Guerois C Parquet A Vicariot M Efficacite de l'inactivation virale des concentres de facteur VIII et IX par procede solvant-detergent La Presse Medicale 20 1991 1163 1166
9. (abstr) Panicucci F Felloni L Vannini A In vitro and In vivo study of an italian solvent/detergent treated high purity factor VIII concentrate XIX International Congress of the World Federation of Hemophilia Washington, DC 1990 30
10. Di Paolantonio T Mariani G Ghirardini A Low risk of transmission of the human immunodeficiency virus by a solvent/detergent treated commercial factor VIII concentrate J Med Virol 36 1992 71 74
11. Presented in Athens Mariani G Di Paolantonio T Baklaja R Poster entitled low risk of transmission of hepatitis C virus (HCV) by a high purity solvent/detergent factor VIII concentrate 1992 Ad Hoc Study Group of the Fondazione Dell'emofilia Italy
12. (abstr) Gomperts E Cox D Courter S Long term safety surveillance in hemophilia A patients receiving a plasma derived mAb purified FVII concentrate Meeting of the National Hemophilia Foundation Tampa, FL 1991
13. (abstr) (suppl) Perret BA Baumagartner C Meili E Zwei Jahre Erfahrungen mit Gerinnungsfaktor VIII-und IX-Konzentraten. Die Mittels Losungmittel Und Detergens Sterilisiert Wurden Schwiez Med Wschr 119 1989 28
14. (abstr) Perret BA Poorbeik M Morell A Klinishe Prufung von Premofil M SRK, Einem Mit Monoklonalen Antikorpern Hochgereinigten gerinnungsfaktor VIII-Konzentrat Aus Human-plasma Schweiz Med Wschr 121 1992 1624
15. Peerlinck K Arnout J Tamise M In vitro and in vivo evaluation of two factor VIII concentrates virally inactivated by solvent-detergent or by pasteurization Acta Clinica Belgica 46 1991 298 304
16. Mannucci PM Gdovin S Gringeri A Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses Ann Intern Med 120 1994 1 7
17. Purcell PH Mannucci PM Gdovin S Virology of hepatitis A epidemic in Italy Vox Sang 67 suppl 4 1994 2 7
18. Vermylen J Peerlinck K Review of the hepatitis A epidemics in hemophiliacs in Europe Vox Sang 67 suppl 4 1994 8 11
19. Mosely JW Mowicki MJ Kasper CK Hepatitis A virus transmission by blood products in the United States Transfusion Safety Study Group Vox Sang 67 suppl 1 1994 24 28
20. Mosely JW Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States Vox Sang 67 suppl 4 1994 12 15
21. Koblin B Aledort L Hilgartner M A study of hepatitis A virus infection among hemophilia patients in New York City Transfusion 35 1995 362 363
22. Morbid Mortal Wkly Rep 45 1996 29 32
23. Fricke W FDA perspective on and response to the risk of hepatitis A from blood products Vox Sang 67 suppl 4 1994 16 18
24. Torok TJ Parvovirus B19 and human disease Adv Inter Med 37 1992 431 455
25. William MD Cohen VJ Beddall AC Transmission of human parvovirus B19 by coagulation factor concentrates Vox Sang 58 1990 177 181
26. Lyon DJ Chapman CED Matin C Symptomatic parvovirus B19 by coagulation factor concentrates Vox Sang 58 1990 177 181
27. Zanella A Rossi F Cesana C Transfusiontransmitted human parvovirus B19 infection in a thalassemic patient Transfusion 35 1995 769 772
28. Azzi A Ciappi S Zakvrzewska K Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates Am J Hematol 39 1992 228 230
29. Horowitz B Virus sterilization by treatment with tri (N-butyl) phosphate/detergent mixtures Inserm 175 1989 365 372
30. Addiego JE Gomperts E Liu SL Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography Thromb Haemost 67 1992 19 27
31. Furlan M Lammle B Aeberhard A Virusinactivated factor VIII concentrate prevents postoperative bleeding in a patient with von Willebrand's disease Transfusion 28 1988 489 492
32. Bermtorp E Bjorkman S Marlsson Biochemical and in vivo properties of high purity factor IX concentrates Thromb Haemost 70 1993 768 773
33. Taliani G Guerra E Rosso R Hapatitis C virus infection in hypogammaglobulinemic patients receiving longterm replacement therapy with intravenous immunoglobulin Transfusion 35 1995 103 107
34. Ebeling F Baer M Hormila P Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients Vox Sang 69 1995 91 94
35. Sponsored by MRMC, FDAm NIH, Bethesda, MD Fibrin Sealant Characteristics and Clinical Uses, Symposium 1994 34
36. Inbal A Epstein O Blickstein D Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders Blood Coagul Fibrinolysis 4 1993 599 604
37. Solheim BG Svennevig JL Mohr B The use of Octaplas In patients undergoing open heart surgery Muller-Buerghaus G DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation 1993 Elsevier Science 253 262
38. Moake JL Rudy CK Troll JH Unusually large plasma factor VIII: von Willebrand factor multimers In chronic relapsing thrombotic thrombocytopenia purpura N Engl J Med 307 1982 1432 1435
39. Moake JL Chintagumpala M Turner N Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura Blood 84 1994 490 497